Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Cash & Current Investments (2024 - 2025)

BioAge Labs (BIOA) has disclosed Cash & Current Investments for 2 consecutive years, with $281.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 20.67% to $281.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $281.1 million through Dec 2025, down 20.67% year-over-year, with the annual reading at $281.1 million for FY2025, 20.67% down from the prior year.
  • Cash & Current Investments hit $281.1 million in Q4 2025 for BioAge Labs, down from $285.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $354.3 million in Q4 2024 to a low of $174.0 million in Q1 2024.